The C.A.M. Report
Complementary and Alternative Medicine: Fair, Balanced, and to the Point
  • About this web log

    This blog ran from 2006 to 2016 and was intended as an objective and dispassionate source of information on the latest CAM research. Since my background is in pharmacy and allopathic medicine, I view all CAM as advancing through the development pipeline to eventually become integrated into mainstream medical practice. Some will succeed while others fail. But all are treated fairly here.

  • About the author

    John Russo, Jr., PharmD, is president of The MedCom Resource, Inc. Previously, he was senior vice president of medical communications at, a complementary and alternative medicine website.

  • Common sense considerations

    The material on this weblog is for informational purposes. It is not medical advice or counsel. Be smart, consult your health professional before using CAM.

  • Recent Posts

  • Recent Comments

    Augmentation therapy for resistant depression

    When a second antidepressant drug is added to an existing antidepressant, it’s called “combination pharmacotherapy.”

    When a non-antidepressant agent is added, it’s “augmentation treatment.”

    Examples of augmentation therapy…

    Omega-3 fatty acids

    • Treatment with ethyl-eicosapentaenoate (EPA) at 1 gram/day was effective for depression in patients who remained depressed despite adequate standard therapy.
    • Reversal of drug resistance by EPA may result from an immunological mechanism.
    • In addition, EPA might enhance the action of some antidepressants, by keeping in the brain longer.

    S-adenosyl methionine (SAMe)

    • Among partial and nonresponders to serotonin reuptake inhibitors (SSRIs) or venlafaxine (Effexor), augmentation with SAMe lead to a response rate of 50% and a remission rate of 43%.

    Augmentation also includes adding pharmacologic agents, not usually used to treat depression.

    The bottom line?
    Dr. George Papakostas from the Massachusetts General Hospital in Boston tells us that unfortunately, many patients remain symptomatic despite the addition of nonpharmacologic (and pharmacologic) augmentation treatments. He concludes, “Clearly, there is an urgent need to develop safer, better tolerated, and more effective treatments for major depressive disorder.

    5/31/08 14:28 JR

    Leave a Comment

    You must be logged in to post a comment.